Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP + Interferon or Rituximab in B-Cell Lymphoma
NCT00004039Phase 2Withdrawn
- Sponsor
- Hoag Memorial Hospital Presbyterian
- Start
- Jun 1998
- Primary completion
- Jan 2000
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, interferon alfa in B cell lymphoma, sponsored by Hoag Memorial Hospital Presbyterian. Planned start Jun 1998; status: withdrawn.
02
Drugs
rituximabinterferon alfa
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT00004039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004039.